Table 2.

Vulvar Vestibulitis Clinical Trial Secondary Outcomes by Treatment Allocation

	Placebo-Placebo			Lidocaine-Placebo
	n	Mean Baseline	Mean Change	n	Mean Baseline	Mean Change
Daily pain log	32	1.97	−0.47±0.77	32	2.01	− 0.53±1.63
Intercourse pain log	26	5.72	−1.97±2.47	21	5.52	−1.92±1.82
Intercourse frequency (per wk)	32	0.13	−0.02±0.12	33	0.15	−0.02±0.10
Cotton swab test–vestibule	33	21.48	−8.65±6.59	32	19.03	−6.42±7.90
Algesiometer	32	9.53	6.97±8.18	32	9.88	3.10±9.64
Pelvic muscle pain (maximum pain)	33	1.15	−0.12±0.86	32	1.16	−0.23±0.92
McGill-Short Form total score	29	13.74	− 4.57±5.86	27	12.32	− 3.10±6.77
Neuropathic Pain Scale	31	41.90	−13.39±14.42	30	44.78	−12.17±17.02
Profile of Mood State Summary	24	85.58	− 4.68±17.37	29	88.17	− 2.15±20.75
Becks Depression Inventory	29	8.62	−1.92±5.44	30	11.17	−0.86±5.90
Brief Pain Inventory Interference	31	20.9	− 6.55±13.81	30	21.37	−3.80±20.25
Index of Sexual Satisfaction	28	59.82	0.69±9.28	24	64.92	0.43±11.71

Mean change is week 0 to 12±standard deviation.

^*Only significant desipramine–lidocaine interactions are displayed.